Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1938 1
1939 5
1940 1
1941 1
1942 1
1946 2
1947 3
1948 5
1949 2
1950 12
1951 13
1952 35
1953 21
1954 9
1955 12
1956 9
1957 22
1958 17
1959 21
1960 11
1961 13
1962 28
1963 48
1964 34
1965 42
1966 43
1967 40
1968 32
1969 40
1970 41
1971 40
1972 55
1973 60
1974 64
1975 62
1976 94
1977 84
1978 89
1979 125
1980 140
1981 169
1982 222
1983 209
1984 259
1985 294
1986 311
1987 384
1988 394
1989 428
1990 523
1991 574
1992 633
1993 752
1994 826
1995 980
1996 1115
1997 1330
1998 1483
1999 1834
2000 2162
2001 2500
2002 2988
2003 3491
2004 4169
2005 5046
2006 5802
2007 6345
2008 7425
2009 8176
2010 9255
2011 10532
2012 12080
2013 13236
2014 14838
2015 15972
2016 16985
2017 18133
2018 20167
2019 22926
2020 26528
2021 30095
2022 31140
2023 331
Text availability
Article attribute
Article type
Publication date

Search Results

273,822 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Fengshuai
Page 1
Did you mean feng shuai lu (2 results)?
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.
von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. von Eyben FE, et al. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16. Eur J Nucl Med Mol Imaging. 2018. PMID: 29247284 Free PMC article. Review.
The treatment with (177)Lu-PSMA-617 and (177)Lu-PSMA for imaging and therapy (I&T) had mainly transient adverse effects. ...CONCLUSIONS: As for patients with mCRPC, treatment with (177)Lu-PSMA-617 RTL and (177)Lu-PSMA I&T gave better effects an …
The treatment with (177)Lu-PSMA-617 and (177)Lu-PSMA for imaging and therapy (I&T) had mainly transient adverse effects. . …
First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2.
Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, Bal C. Ballal S, et al. Pharmaceuticals (Basel). 2021 Nov 24;14(12):1212. doi: 10.3390/ph14121212. Pharmaceuticals (Basel). 2021. PMID: 34959613 Free PMC article.
The FAPi agents, [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2), were administered in two different groups of patients. ...The first clinical dosimetry study demonstrated significantly higher tumor absorbed doses with [(177)Lu]L
The FAPi agents, [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2), were administered in two differen …
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC.
Hänscheid H, Hartrampf PE, Schirbel A, Buck AK, Lapa C. Hänscheid H, et al. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2566-2572. doi: 10.1007/s00259-020-05177-z. Epub 2021 Jan 15. Eur J Nucl Med Mol Imaging. 2021. PMID: 33452632 Free PMC article.
It was tested in selected patients whether the substance is superior to [(177)Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in organs and tumours after [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC were compared intraindividually in five …
It was tested in selected patients whether the substance is superior to [(177)Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in or …
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.
Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Schuchardt C, et al. J Nucl Med. 2022 Aug;63(8):1199-1207. doi: 10.2967/jnumed.121.262713. Epub 2021 Dec 9. J Nucl Med. 2022. PMID: 34887335
Despite the longer half-life of (177)Lu-PSMA-617, the renal dose was lower for (177)Lu-PSMA-617 than for (177)Lu-PSMA I&T (0.77 vs. 0.92 Gy/GBq, P = 0.0015). ...No nephrotoxicity was observed after either (177)Lu-PSMA I&T or (177)Lu-PSMA …
Despite the longer half-life of (177)Lu-PSMA-617, the renal dose was lower for (177)Lu-PSMA-617 than for (177)Lu-PSMA I …
Lutetium Lu 177 Dotatate.
[No authors listed] [No authors listed] 2020 Aug 17. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. 2020 Aug 17. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. PMID: 30000023 Free Books & Documents. Review.
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. No information is available on the use of lutetium Lu 177 dotatate during breastfeeding. The ma …
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroen …
Lutetium-177-PSMA-617: A Vision of the Future.
Chandran E, Figg WD, Madan R. Chandran E, et al. Cancer Biol Ther. 2022 Dec 31;23(1):186-190. doi: 10.1080/15384047.2022.2037985. Cancer Biol Ther. 2022. PMID: 35220877 Free PMC article.
The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[(177)Lu]Lu-PSMA-617 in post-chemotherapy mCRPC. This journal club reviews the VISION trial in the context of the earlier TheraP trial of [(177)Lu]Lu-PSMA-617 in mCRP …
The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[(177)Lu]Lu-PSMA-617 in post-chemotherap …
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, de Ridder C, Stuurman D, Konijnenberg MW, van Weerden WM, de Jong M, Nonnekens J. Ruigrok EAM, et al. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1339-1350. doi: 10.1007/s00259-020-05057-6. Epub 2020 Oct 23. Eur J Nucl Med Mol Imaging. 2021. PMID: 33094433 Free PMC article.
Autoradiography assays on cryosections of human salivary and renal tissues revealed [(177)Lu]Lu-PSMA-617 to have the lowest binding to these healthy organs compared with [(177)Lu]Lu-PSMA-I&T. ...CONCLUSION: [(177)Lu]Lu-PSMA-617 has th …
Autoradiography assays on cryosections of human salivary and renal tissues revealed [(177)Lu]Lu-PSMA-617 to have the lowest bi …
Modelling of the 177mLu/177Lu radionuclide generator.
Bhardwaj R, Wolterbeek HT, Denkova AG, Serra-Crespo P. Bhardwaj R, et al. Appl Radiat Isot. 2020 Dec;166:109261. doi: 10.1016/j.apradiso.2020.109261. Epub 2020 Jul 10. Appl Radiat Isot. 2020. PMID: 32961525 Free article.
In order to determine the potential of (177m)Lu/(177)Lu radionuclide generator in (177)Lu production it is important to establish the technical needs that can lead to a clinically acceptable (177)Lu product quality. ...The dissociation rate constants l …
In order to determine the potential of (177m)Lu/(177)Lu radionuclide generator in (177)Lu production it is important to …
MiR-20a regulates fibroblast-like synoviocyte proliferation and apoptosis in rheumatoid arthritis.
Wei XJ, Li XW, Lu JL, Long ZX, Liang JQ, Wei SB, Lu CX, Lu WZ. Wei XJ, et al. Eur Rev Med Pharmacol Sci. 2020 Jul;24(14):7578. doi: 10.26355/eurrev_202007_22253. Eur Rev Med Pharmacol Sci. 2020. PMID: 32744683
Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, "MiR-20a regulates fibroblast-like synoviocyte proliferation and apoptosis in rheumatoid arthritis, by X.-J. Wei, X. …
Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originali …
Comparison of biological properties of [177 Lu]Lu-ProBOMB1 and [177 Lu]Lu-NeoBOMB1 for GRPR targeting.
Rousseau E, Lau J, Zhang Z, Zhang C, Kwon D, Uribe CF, Kuo HT, Zeisler J, Bratanovic I, Lin KS, Bénard F. Rousseau E, et al. J Labelled Comp Radiopharm. 2020 Feb;63(2):56-64. doi: 10.1002/jlcr.3815. Epub 2020 Jan 11. J Labelled Comp Radiopharm. 2020. PMID: 31715025
Lu-NeoBOMB1 had better binding affinity for GRPR than Lu-ProBOMB1 (K(i) values: 2.26 0.24 and 30.2 3.23nM). [(177) Lu]Lu-ProBOMB1 was obtained in 53.7 5.4% decay-corrected radiochemical yield with 444.2 193.2 GBq/mumol molar activity and >95% radioc
Lu-NeoBOMB1 had better binding affinity for GRPR than Lu-ProBOMB1 (K(i) values: 2.26 0.24 and 30.2 3.23nM). [(177) Lu]
273,822 results
You have reached the last available page of results. Please see the User Guide for more information.